CU06 (Rivasterat) – DME
An oral drug candidate designed to normalize endothelial dysfunction
Therapeutic Function of CU06 in Diabetic Macular Edema
Ph2a results of Rivasterat
Dose- & treatment duration-dependent BCVA improvement in patients with poor vision
Modality
Oral small molecule
Mechanism of Action
Vascular normalization and functional restoration through improvement of endothelial dysfunction
(Active ingredient: Rivasterat)
Indication
Diabetic macular edema (DME)
Development Status
U.S. Phase 2a clinical study report (CSR) received (2024.04)
U.S. IND submission for Phase 2b planned in 2026
Key Differentiators
A differentiated therapeutic approach focused on endothelial dysfunctionVisual acuity improvement and safety observed in a Phase 2a trialOral administration designed to offer greater treatment convenience than intravitreal injections
Market Opportunity
As an oral candidate, CU06 has the potential to reduce the treatment burden associated with intravitreal anti-VEGF therapy, the current standard of care. Subject to further clinical validation, it aims to expand treatment options for patients and clinicians as a standalone therapy or as a complementary treatment alongside existing therapies.
Development & Partnerships
Pursuing global out-licensing opportunities